Singapore GLP-1 clinics deeper-cut 2026: per-clinic pricing, MOH posture, Bangkok-hop tradeoff
The Singapore GLP-1 clinic layer beyond the existing buyers guide. Per-clinic pricing for the four most-routable Singapore providers, MOH-licensed-product reality, the Wegovy-vs-Ozempic supply picture, and when the 2h20 Bangkok flight beats the local cost.
The existing Singapore buyers guide covers the regulatory frame and the four-clinic shape. This post goes one click deeper · per-clinic 2026 pricing on what's actually in stock, MOH-licensed-product specifics, and the cost calculation that pushes a meaningful share of SG-resident expats onto the 2h20 Bangkok-hop relationship for resupply while keeping a Singapore clinic anchor for continuity.
What MOH licenses today
The Singapore Health Sciences Authority maintains the active register of weight-management medications. As of May 2026 the register includes:
- Wegovy (semaglutide 2.4mg) · weight-management indication, prescribed at private clinics + MOH-licensed pharmacies
- Ozempic (semaglutide diabetes label) · diabetes indication, off-label weight-management prescribing common but not insured under most private plans for that use
- Mounjaro (tirzepatide diabetes label) · diabetes indication, similar off-label dynamics
- Saxenda (liraglutide 3.0mg) · weight-management indication, daily injection
Zepbound (tirzepatide weight-management label) is not yet on the SG active register as of May 2026. Wegovy is the cleanest weight-management-indication route; Mounjaro is the cleanest tirzepatide route via diabetes prescribing and off-label use.
Per-clinic pricing, May 2026
Premium private clinics in Singapore run higher than the Bangkok premium-hospital tier. The four most-routable Singapore GLP-1 providers in our catalog:
| Clinic | Wegovy 2.4mg | Mounjaro 5mg | Mounjaro 10mg | Consult fee |
|---|
Converted to USD at the May 2026 rate: roughly USD 660 to 1,030 for Wegovy, USD 510 to 1,000 for Mounjaro depending on dose. Compare to the Bangkok mid-tier pricing of USD 220 to 460 for Mounjaro 5mg to 10mg + the USD 90 to 220 round-trip flight.
The Bangkok-hop math from Singapore
Singapore is the geographically-closest expat market to Bangkok in our SE Asia matrix. SQ + Scoot + Thai + AirAsia all run multiple daily SIN-BKK flights at 2h20. Round-trip economy 30-day-advance booking lands USD 90 to 220 off-peak.
The break-even calculation per pen, comparing same-dose Mounjaro at the Singapore mid-tier vs the Bangkok mid-tier with one round-trip flight:
- Singapore Mounjaro 5mg per month: ~USD 510 (no flight)
- Bangkok Mounjaro 5mg per month + flight amortized over 8-week supply: ~USD 220 + ~USD 75 flight share = ~USD 295
The Bangkok hop saves roughly USD 200 to 300 per month at the mid-tier even with the flight cost factored in. At higher doses (10mg, 12.5mg, 15mg) the absolute savings grow proportionally because the per-pen price scales with dose.
The cost-equation does not include time. A round-trip Bangkok visit takes a half-day each way + a clinic appointment in Bangkok = roughly one full work-day of opportunity cost every 8 to 12 weeks. For SG residents whose hourly rate is high enough to make that calculation favor staying, the local-clinic premium is the right answer. For everyone else the Bangkok hop math wins.
When to keep a Singapore clinic anchor anyway
Two scenarios where a Singapore clinic relationship still earns its keep:
1. Insurance coverage. Some Singapore private health plans (Aviva, Prudential, AIA) cover Wegovy at MOH-licensed clinics with the weight-management indication. None of them reimburse the Bangkok-hop pen. If your insurance covers ~70% of the SG private cost, the local route wins on out-of-pocket. 2. Clinical continuity for complex cases. Patients with comorbid conditions (T2D, cardiovascular disease, kidney function questions) benefit from a SG-based clinical relationship for the labs and the integrated specialist consults. The Bangkok-hop is well-suited for the GLP-1 prescription itself but not for the broader clinical picture.
What we route to
The matchmaker quiz at /quiz routes Singapore-resident users by goal cluster, urgency, and budget signal. SG users who pick "ready" + "full optimization" + premium-budget land on the Singapore-clinic route by default. SG users who pick "ready" + "meaningful" + cost-conscious-budget land on a hybrid recommendation: Bangkok-hop for the prescription + Singapore-clinic for labs and follow-up.
The full per-vendor scorecards for the SG-routable clinics live at /vendor. The Bangkok-hop playbook with the cross-border mechanics is at /blog/bangkok-glp1-hop-expat-playbook-2026.
One email a week. Catalog updates, new posts, BKK supply state. No spam, no MLM. What lands in the inbox →
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
Mira Tanaka is the editor at panya, based in Bangkok. Editor at Panya. Covers peptide therapeutics with a focus on the routing decisions mainstream adults actually face. Corrections, tips, or push-back: editor@panya.health.
The next-gen GLP-1 horizon: orforglipron, CagriSema, MariTide, and which to actually wait for
Three drugs are about to change the GLP-1 conversation again. Orforglipron just got FDA approval. CagriSema is in phase 3 readouts. MariTide is the longer-tail bet. Here's the honest read on which deserves your patience and which is hype.
Tirzepatide for type 2 diabetes: how it's different from the weight-loss case
Most coverage of tirzepatide treats it as a weight-loss drug. For T2D patients, the dose ramp, dosing goal, comparison frame, and what success looks like are all different.
Tirzepatide and resistance training: the protocol that actually preserves muscle
Lifting consistently while on tirzepatide is the single most actionable thing you can do for body composition outcomes. Specific exercises, sets, frequency, and timing relative to dose.